AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9023388
Drug: Bepanthen cream
RxNorm normalized name: Bepanthen
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bepanthen cream applied to randomly selected parts of treatment fields
Trial: 9023388
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical ointment (control)
Trial: 2003042
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (300 micrograms/day)
Trial: 6370439
Drug: Oxaprozin 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaprozin 1,200 mg once daily
Trial: 6370439
Drug: Phenylbutazone 100
RxNorm normalized name: phenylbutazone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 100 mg four times daily
Trial: 12056707
Drug: Oral capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine (1250 mg/m2 twice daily, on days 1‐14 every 21 days)
Trial: 12056707
Drug: Intravenous 5‐FU/leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5‐FU/leucovorin (Mayo Clinic regimen)
Trial: 24801171
Drug: Oral capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine
Trial: 12056707
Drug: Intravenous 5‐FU/leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5‐FU/leucovorin
Trial: 10496113
Drug: CES plus
RxNorm normalized name: Ascorbic Acid/Calcium/Selenium/Vitamin A/Vitamin E/Zinc 250 MG-25 MG-50 MCG-5000 IU-200 IU-7.5 MG Oral Capsule, Liquid Filled [ACES PLUS ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CES plus low dose caffeine (150 mg/l)
Trial: 10496113
Drug: CES plus
RxNorm normalized name: Ascorbic Acid/Calcium/Selenium/Vitamin A/Vitamin E/Zinc 250 MG-25 MG-50 MCG-5000 IU-200 IU-7.5 MG Oral Capsule, Liquid Filled [ACES PLUS ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CES plus medium dose caffeine (225 mg/l)
Trial: 10496113
Drug: CES placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CES placebo (68.8 g/l)
Trial: 6162280
Drug: Irradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation therapy combined with vitamin A palmitate (1.5 million IU/day; total dose 30 million IU), applied orally
Trial: 7084867
Drug: Irradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation therapy combined with vitamin A palmitate
Trial: 30692558
Drug: Artemether-Lumefantrine (A-L)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-Lumefantrine (A-L) in fed state
Trial: 28122892
Drug: alemtuzumab 30
RxNorm normalized name: alemtuzumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alemtuzumab 30 mg by intravenous infusion every other day three times a week for 12 weeks
Trial: 26100413
Drug: Once monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once monthly administration of vitamin D3 (25,000 IU)
Trial: 26100413
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of a fixed-dose combination of vitamin D3 (800 IU) and calcium (1000 mg)
Trial: 19386747
Drug: Lower protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower protein formula (1.77 and 2.2 g protein/100 kcal)
Trial: 19386747
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein formula (2.9 and 4.4 g protein/100 kcal)
Trial: 15660234
Drug: Continuous SCT
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous SCT nasal spray at a dose of 200 IU/day, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Trial: 15660234
Drug: Cyclic SCT
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic SCT nasal spray at a dose of 200 IU/day on alternating 15 days per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Trial: 15660234
Drug: Cyclic SCT
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic SCT nasal spray on 10 days consecutively per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Trial: 12814035
Drug: G115 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G115 100 mg bid for three months
Trial: 8824658
Drug: Morning dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosage of 40 mg omeprazole
Trial: 8824658
Drug: Evening dosage
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening dosage of 40 mg omeprazole
Trial: 26927479
Drug: APOLO-Bari program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APOLO-Bari program for one year in addition to treatment as usual
Trial: 17190530
Drug: Eletriptan 20
RxNorm normalized name: eletriptan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan 20 mg
Trial: 16982287
Drug: Eletriptan 40
RxNorm normalized name: eletriptan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan 40 mg
Trial: 16982287
Drug: Eletriptan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan 80 mg
Trial: 12772414
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional methods including hyperbaric oxygen, vasodilator, energy preparation such as ATP, CoA, and dexamethasone)
Trial: 9135404
Drug: Inhaled 100%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 100% oxygen
Trial: 9135404
Drug: Inhaled air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled air (control)
Trial: 8201695
Drug: Postoperative cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative cisplatin chemotherapy (3 courses of 90 mg/m² given for 3 consecutive days at monthly intervals)
Trial: 8201695
Drug: Postoperative cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative cisplatin chemotherapy
Trial: 8201695
Drug: Postoperative cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative cisplatin chemotherapy and Observation
Trial: 3284752
Drug: Mianserin (30-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (30-80 mg daily)
Trial: 3284752
Drug: Trazodone (150-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (150-400 mg daily)
Trial: 1297641
Drug: Controlled-release naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release naproxen (750-mg tablet) after fasting
Trial: 1297641
Drug: Controlled-release naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release naproxen (750-mg tablet) after a standard meal
Trial: 1297641
Drug: Controlled-release naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release naproxen with food
Trial: 1297641
Drug: Controlled-release naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release naproxen fasting vs postprandial
Trial: 26597952
Drug: Edaravone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (30 mg twice per day for 14 days)
Trial: 26597952
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 ml saline twice per day for 14 days)
Trial: 18836845
Drug: Serum procalcitonin
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum procalcitonin (PCT) with a cut-off value of 0.85 ng/ml
Trial: 17164307
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (10 g testosterone gel daily for 24 weeks)
Trial: 15976211
Drug: Preoperative field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative field block plus rofecoxib, 50 mg preoperatively and for 5 days postoperatively (PLR)
Trial: 11999936
Drug: Powered toothbrush
RxNorm normalized name: Pro Clean Spinbrush Powered Toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powered toothbrush fitted with a modified orthodontic brush head (Braun Oral-B Plaque Remover 3D)
Trial: 10210035
Drug: Vigabatrin (VGB,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB, 2‐4 g daily)
Trial: 10210035
Drug: Sodium Valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Valproate (VPA, 1‐2 g daily)
Trial: 7790126
Drug: Self-reported illicit
RxNorm normalized name: Illicium difengpi bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported illicit drug use
Trial: 30765389
Drug: Pazopanib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib with concomitant GAS therapy
Trial: 30765389
Drug: Pazopanib without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib without concomitant GAS therapy
Trial: 28604926
Drug: ADS-5102 (amantadine)
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADS-5102 (amantadine) 274 mg administered orally at bedtime for up to 25 weeks
Trial: 28833562
Drug: ADS-5102 (amantadine)
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADS-5102 (amantadine) 274 mg
Trial: 25353053
Drug: Tadalafil (TAD)
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil (TAD) 5mg coadministered with finasteride (FIN) 5mg once daily for 26 weeks
Trial: 25353053
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) coadministered with finasteride (FIN) 5mg once daily for 26 weeks
Trial: 20593411
Drug: AMG 785
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 785 (0.1, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously or 1 or 5 mg/kg intravenously)
Trial: 17483532
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) 20 mg subcutaneously daily
Trial: 15470215
Drug: Lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (100 mg per day)
Trial: 9583069
Drug: Laparoscopic retroperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic retroperitoneal uterine suspension (n = 32)
Trial: 7637176
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg of droperidol added to buprenorphine
Trial: 7637176
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of droperidol added to buprenorphine
Trial: 7637176
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of droperidol added to buprenorphine
Trial: 2759074
Drug: Isotonic glucose-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic glucose-electrolyte solution
Trial: 17375008
Drug: 595 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595 nm pulse dye laser therapy (PDL) with settings: spot diameter 5 mm, pulse duration 0.45 ms, fluence 9 J/cm2, 5 passes at 1 Hz, with cryogen spray cooling.
Trial: 17375008
Drug: 595 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595 nm pulse dye laser therapy (PDL)
Trial: 7650078
Drug: iohexol 300
RxNorm normalized name: IOHEXOL 300MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 300 mgI/ml (100 ml, n = 17)
Trial: 7650078
Drug: ioversol 320
RxNorm normalized name: IOVERSOL 320MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioversol 320 mgI/ml (100 ml, n = 13)
Trial: 7650078
Drug: iopromide 300
RxNorm normalized name: IOPROMIDE 300mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopromide 300 mgI/ml (75 ml, n = 12)
Trial: 7650078
Drug: iopentol 300
RxNorm normalized name: iopentol 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopentol 300 mgI/ml (100 ml, n = 11)
Trial: 342692
Drug: L-histidine 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-histidine 4.5 g daily for 30 weeks
Trial: 31419622
Drug: Multi-component nurse-led
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component nurse-led intervention including nurse-led care coordination, nurse-managed medication protocols and adherence support, home BP monitoring, and electronic health records support tools.
Trial: 28095832
Drug: Motion-sensor biofeedback
RxNorm normalized name: GLUCOSE SENSOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motion-sensor biofeedback treatment in addition to guidelines-based care
Trial: 26383176
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy 3 times a week for 4 weeks
Trial: 23149074
Drug: Gazpacho consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gazpacho consumption (250 g/week increase)
Trial: 18470670
Drug: No additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additive treatment (Control)
Trial: 10719612
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg AS 195
Trial: 10719612
Drug: 720 mg
RxNorm normalized name: pancreatin 720 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mg AS 195
Trial: 10719612
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg AS 195 and 720 mg AS 195
Trial: 3677541
Drug: Nicainoprol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicainoprol (100 mg intravenous infusion)
Trial: 3677541
Drug: Nicainoprol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicainoprol (200 mg oral dose)
Trial: 3677541
Drug: Nicainoprol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicainoprol (both doses)
Trial: 24903387
Drug: Renin-angiotensin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin inhibitors
Trial: 3246461
Drug: L-tryptophan supplementation
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan supplementation
Trial: 10319775
Drug: Low-dose sevoflurane
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sevoflurane (end-tidal concentration, 0.25%)
Trial: 6783419
Drug: Cholestyramine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine administration
Trial: 7588486
Drug: Neomycin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin administration
Trial: 2277372
Drug: 80‐mg terconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80‐mg terconazole suppositories for 3 days
Trial: 2277372
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate suppositories for 7 days
Trial: 2277372
Drug: Placebo suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories for 7 days
Trial: 6985830
Drug: Weekly cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly cyclophosphamide, cytosine arabinoside, and methotrexate (CAM)
Trial: 6985830
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily cytosine arabinoside and thioguanine (AT)
Trial: 6985830
Drug: Overall response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Overall response rate for both treatments
Trial: 11758850
Drug: UFT 300
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 300 mg/m2/day with oral Folinic acid 7.5 mg/dose for 21 days
Trial: 9212017
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by concurrent treatment (Arm 1): vinblastine (VB) 5 mg/M2 I.V. bolus weekly for weeks 1-5, cisplatin (DDP) 100 mg/M2 days 1 and 29, DDP 75 mg/M2 days 50, 71, and 92, with daily RT starting on day 50 (total dose 63 Gy in 34 fractions over 7 weeks).
Trial: 9212017
Drug: Immediate concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate concurrent chemotherapy/radiotherapy (Arm 2): RT started on day 1 (total dose 69.6 Gy in 58 fractions of 1.2 Gy bid, 5 days per week for 6 weeks), DDP 50 mg/M2 i.v. days 1 and 8, oral VP-16 50 mg b.i.d. during the first 10 days of RT, repeated beginning day 29.
Trial: 2906171
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice daily for 3 days
Trial: 29289726
Drug: Annual application
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual application of 30% SDF solution
Trial: 29289726
Drug: Three applications
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three applications of 30% SDF at weekly intervals
Trial: 29289726
Drug: Three applications
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three applications of 5% NaF varnish at weekly intervals
Trial: 17196048
Drug: Topiramate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (25 to 400 mg/day over 8 weeks, continued for 4 additional weeks)
Trial: 14751054
Drug: i.v. Anqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. Anqi and oral consecutive strategy
Trial: 11202421
Drug: Papaverine 30
RxNorm normalized name: papaverine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine 30 mg + phentolamine 1 mg (Control)
Trial: 8992678
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (900 mg) + Metoclopramide (10 mg)
Trial: 31542757
Drug: CPPOpt Guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPPOpt Guided Therapy (automated CPP target based on cerebrovascular reactivity)
Trial: 24958326
Drug: Empagliflozin 50
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 50 mg
Trial: 16979793
Drug: Alcohol-based waterless
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol-based waterless scrub solution (ABWL)
Trial: 16979793
Drug: Brush-based iodine
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush-based iodine solution (BBIS)
Trial: 16979793
Drug: Alcohol-based water-aided
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol-based water-aided scrub solution (ABWA)
Trial: 9173664
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three solutions
Trial: 12520092
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in beta(1)- or beta(2)-adrenergic receptor mRNA or protein
Trial: 7806681
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (Augmentin or clindamycin) with scaling and rootplaning
Trial: 7806681
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy with scaling and rootplaning
Trial: 2588997
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of plain 0.5% bupivacaine
Trial: 2588997
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of plain 0.5% bupivacaine
Trial: 2588997
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of plain 0.5% bupivacaine
Trial: 23179201
Drug: CHO constituent
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO constituent (50 g)
Trial: 23179201
Drug: New DSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New DSF (400 ml)
Trial: 23179201
Drug: Control product
RxNorm normalized name: Patch test control product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control product (400 ml)